8-K: Pasithea Therapeutics Enters At-The-Market Offering Agreement to Sell Up to $2.076 Million in Common Stock

Pasithea Therapeutics Corp. has entered into an agreement to sell up to $2.076 million of its common stock through an at-the-market offering.

Summary

• Pasithea Therapeutics Corp. has entered into an At The Market Offering Agreement with H.C. Wainwright & Co., LLC to sell shares of its common stock.
• The company may sell up to $2,076,000 worth of common stock, based on limitations of General Instruction I.B.6 of Form S-3.
• The sales will be made through the Sales Agent, H.C. Wainwright & Co., LLC, either directly on the Nasdaq or in privately negotiated transactions with the company's prior written approval.
• The company will set parameters for the sale, including the number of shares, time period, daily limits, and minimum price.
• The Sales Agent will receive a 3.0% cash commission on the gross sales price of the shares sold.
• The company will also reimburse the Sales Agent for legal fees and expenses, up to $100,000, plus additional fees for due diligence sessions related to financial filings.
• The offering will terminate upon the sale of all shares or termination of the agreement by either party.

Sentiment

Score: 6

Explanation: The document is neutral to slightly positive. It outlines a standard financial transaction for a public company. While it provides a means for raising capital, it also introduces potential dilution for existing shareholders. The terms are standard for this type of agreement.

Positives

• The agreement provides Pasithea Therapeutics with a flexible way to raise capital.
• The at-the-market offering allows the company to sell shares gradually, potentially minimizing market impact.
• The company has the option to suspend offers at any time.

Negatives

• The company will incur a 3.0% commission on all shares sold through the sales agent.
• The company will incur additional expenses for legal fees and due diligence.
• There is no guarantee that the company will be able to sell all of the shares.

Risks

• The company may not be able to sell all of the shares at the desired price.
• The offering could dilute existing shareholders' ownership.
• The company is subject to market conditions and investor demand.

Future Outlook

The company intends to use the proceeds from the offering for general corporate purposes, but specific details are not provided in this document.

Industry Context

At-the-market offerings are a common method for publicly traded companies, particularly in the biotech sector, to raise capital. This allows for flexible funding without the need for a large, single offering.

Comparison to Industry Standards

• The 3% commission is within the typical range for at-the-market offerings.
• The legal fee reimbursement is also standard for these types of agreements.
• Other biotech companies such as Amylyx Pharmaceuticals and Biohaven Pharmaceutical have used similar ATM offerings to raise capital.
• The size of the offering, $2.076 million, is relatively small compared to some larger biotech companies, but is appropriate for a company of Pasithea's size and stage.

Stakeholder Impact

• Shareholders may experience dilution of their ownership.
• The company will have additional capital to fund operations.
• The sales agent will earn commissions from the sales.

Next Steps

• The company will begin selling shares through the sales agent.
• The company will file necessary supplements to the prospectus.
• The company will monitor market conditions and investor demand.

Key Dates

Keywords

at-the-market offering, common stock, capital raise, securities, H.C. Wainwright, Pasithea Therapeutics, equity financing